Equities analysts expect that Otonomy Inc (NASDAQ:OTIC) will report $250,000.00 in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Otonomy’s earnings, with estimates ranging from $150,000.00 to $340,000.00. Otonomy reported sales of $270,000.00 in the same quarter last year, which would suggest a negative year over year growth rate of 7.4%. The business is scheduled to announce its next quarterly earnings results on Thursday, March 1st.

According to Zacks, analysts expect that Otonomy will report full-year sales of $250,000.00 for the current fiscal year, with estimates ranging from $1.12 million to $2.20 million. For the next financial year, analysts anticipate that the firm will report sales of $8.03 million per share, with estimates ranging from $200,000.00 to $21.70 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Otonomy.

Otonomy (NASDAQ:OTIC) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.15. The firm had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.43 million. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The company’s revenue was down 12.8% compared to the same quarter last year.

Several equities analysts recently commented on OTIC shares. Zacks Investment Research raised shares of Otonomy from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Tuesday, November 14th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $8.00 price objective on shares of Otonomy in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $9.15.

A number of large investors have recently modified their holdings of the stock. Alpine Associates Management Inc. purchased a new position in Otonomy in the 3rd quarter worth approximately $797,000. Dimensional Fund Advisors LP grew its stake in Otonomy by 6.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 436,003 shares of the biopharmaceutical company’s stock worth $1,417,000 after buying an additional 28,204 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Otonomy in the 3rd quarter worth approximately $263,000. Bank of New York Mellon Corp grew its stake in Otonomy by 72.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 596,784 shares of the biopharmaceutical company’s stock worth $1,939,000 after buying an additional 249,845 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in Otonomy in the 3rd quarter worth approximately $126,000. 60.57% of the stock is owned by institutional investors.

Shares of Otonomy (NASDAQ OTIC) traded down $0.05 during trading hours on Thursday, reaching $5.80. 364,700 shares of the company traded hands, compared to its average volume of 383,750. The stock has a market capitalization of $175.96, a PE ratio of -1.80 and a beta of 3.33. Otonomy has a 12 month low of $2.80 and a 12 month high of $21.15.

TRADEMARK VIOLATION WARNING: “$250,000.00 in Sales Expected for Otonomy Inc (OTIC) This Quarter” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/250000-00-in-sales-expected-for-otonomy-inc-otic-this-quarter.html.

About Otonomy

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Get a free copy of the Zacks research report on Otonomy (OTIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Otonomy (NASDAQ:OTIC)

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.